Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2013
10/23/2013CN102600063B Method for preparing curcumin micelle with high medicine loading
10/23/2013CN102585258B Gelatin embolism microsphere and preparation method and application thereof
10/23/2013CN102552274B Application of moving point motor protein small molecular inhibitor to inhibition of tumor cell proliferation
10/23/2013CN102516395B Polypeptide carrier used for improving targeting ability and transfection efficiency of medicine/gene, and purpose thereof
10/23/2013CN102372712B Imidazodiazanaphthalene PI3K (phosphatidyl inositol 3 kinase) and mTOR (mammalian target of rapamycin) dual inhibitor
10/23/2013CN102357071B Taxol-carried nano microbubble and preparation method thereof
10/23/2013CN102276613B Sesquiterpene alkaloid compound as well as preparation method and application thereof
10/23/2013CN102178959B siRNA for inhibiting growth of pulmonary metastasis tumor and oligonucleotide composition and application thereof
10/23/2013CN101965201B Intralymphatic chemotherapy drug carriers
10/23/2013CN101848895B Combination of anti-angiogenic substance and anti-tumor platinum complex
10/23/2013CN101837130B Polyethylene glycol-dipeptide-antitumour drug complex and use thereof
10/23/2013CN101679298B Fused bicyclic heteroaryl derivatives
10/23/2013CN101429198B Banisterine derivant and uses thereof
10/22/2013US8563558 Substituted pyridine urea compounds
10/22/2013US8563556 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts
10/22/2013US8563516 Foxp3 peptide vaccine
10/22/2013US8563507 Method of treating a disease or condition characterized by aberrant epithelial cell proliferation
10/22/2013US8563506 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
10/22/2013US8563249 Receptor gene screening for detecting or diagnosing cancer
10/22/2013US8563000 Melanocortin receptor ligands modified with hydantoin
10/22/2013US8562995 Neoplasm specific antibodies and uses thereof
10/22/2013US8562985 Antibodies to c-Met
10/22/2013US8562977 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
10/22/2013US8562968 Use of stem cells and CD6 depleted stem cells for the induction of tolerance to allogenic transplants and/or for the treatment of leukemia
10/22/2013US8562964 Polymalic acid-based multifunctional drug delivery system
10/22/2013CA2743030C 3-aminocyclopentanecarboxamides as chemokine receptor modulators
10/22/2013CA2621377C Antitumor agent
10/22/2013CA2601640C Use of macrolides for treating intestinal inflammation
10/22/2013CA2580719C Small molecules that replace or agonize p53 function
10/22/2013CA2580150C Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
10/22/2013CA2577309C Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
10/22/2013CA2412626C Il-17 molecules and uses thereof
10/22/2013CA2345375C Chemical structure with affinity for a phospholipid, and marker compound, diagnosis kit, and medicine comprising said structure
10/17/2013WO2013155464A1 Combination therapy for treating cancer
10/17/2013WO2013155385A1 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
10/17/2013WO2013155360A1 A method for preventing neoplastic transformation by inhibition of retinoblastoma protein inactivation
10/17/2013WO2013155346A1 Diagnostic tools for response to 6-thiopurine therapy
10/17/2013WO2013155341A1 Methods and compositions for treating ewings sarcoma family of tumors
10/17/2013WO2013155317A1 Salt form of a human hi stone methyltransf erase ezh2 inhibitor
10/17/2013WO2013155223A1 Compositions and methods for treating cancer
10/17/2013WO2013155218A1 Chirally pure isomers of itraconazole for use as angiogenesis inhibitors
10/17/2013WO2013155103A1 Compositions and methods for inhibiting the activity of lar family phosphatases
10/17/2013WO2013154878A1 Heterocyclic compounds and uses thereof
10/17/2013WO2013154707A1 Co-polymer conjugates
10/17/2013WO2013154503A1 Methods for bladder cancer therapy using baculoviral vectors
10/17/2013WO2013154335A1 Method for preparing furofuran lignan compound
10/17/2013WO2013154303A1 Pyrimidine derivative substituted with novel hydrazine, and use thereof
10/17/2013WO2013154206A1 Anti-fgfr2 antibody
10/17/2013WO2013154045A1 Composition for injectable solution
10/17/2013WO2013153821A1 Pdk4 inhibitor and use thereof
10/17/2013WO2013153800A1 Method for producing lymphocyte cell group consisting mainly of memory t cells
10/17/2013WO2013153559A1 Fulvestrant formulations
10/17/2013WO2013153092A1 Inhibitors of receptor for advanced glycation-end products (rage) for use in treating and/or preventing inflammation- and/or damage-induced cancer
10/17/2013WO2013152717A1 Fused pyrimidine compound, and preparation method, intermediate, composition， and uses thereof
10/17/2013WO2013152683A1 Bicycle substituted pyrazoloneazo derivatives and preparation method and use thereof
10/17/2013WO2013152590A1 Metal-polysaccharide conjugates: compositions,synthesis and methods for cancer therapy
10/17/2013WO2013124874A3 Glucose derivatives bound to arsenic for use in the treatment of tumour
10/17/2013WO2013116821A9 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
10/17/2013WO2012104007A3 7-azaindole derivatives
10/17/2013US20130274309 Compositions and methods for non-parenteral delivery of oligonucleotides
10/17/2013US20130274255 Heterocyclic pyrazole compounds, method for preparing the same and use thereof
10/17/2013US20130274252 Quinazoline derivatives as kinase inhibitors
10/17/2013US20130273651 Differentiated cells suitable for human therapy
10/17/2013US20130273175 Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
10/17/2013US20130273075 Compounds and Method for Modulating Inflammatory Reactions
10/17/2013US20130273042 Treatment of multiple sclerosis
10/17/2013US20130273041 Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant
10/17/2013US20130273039 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
10/17/2013US20130273038 Human cdr-grafted antibody and antibody fragment thereof
10/17/2013US20130273009 Methods to mobilize progenitor/stem cells
10/17/2013US20130273004 Substituted alkylamine derivatives and methods of use
10/17/2013US20130272998 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy
10/17/2013US20130272997 Synthetic mechanical hemostatic composition, method of making and use thereof
10/16/2013EP2650383A1 Ultraconserved regions encoding ncRNAs
10/16/2013EP2650367A1 Human monoclonal antibody
10/16/2013EP2650361A1 Galectin 9-secreting cell, production method for same, and application for same
10/16/2013EP2650309A1 Conjugate of folate and antibody, preparation method and use thereof
10/16/2013EP2650306A1 Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
10/16/2013EP2650295A1 Alpha helix mimetics and methods relating thereto
10/16/2013EP2650293A1 [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
10/16/2013EP2650286A1 Quinazoline derivatives and therapeutic use thereof
10/16/2013EP2650284A1 Heterocyclic derivatives as metabotropic glutamate receptor modulators
10/16/2013EP2650018A2 Antibody-LIGHT fusion products for cancer therapeutics
10/16/2013EP2650017A2 Alpha 5 - beta 1 antibodies and their uses
10/16/2013EP2650013A1 Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
10/16/2013EP2650012A1 Treatment of metastatic stage prostate cancer with degarelix
10/16/2013EP2650000A1 Utilization of copper complexes involving 2-phenyl-3-hydroxy-4(1H)-quinolinone and 1,10-phenanthroline derivatives for the preparation of drugs for the treatment of tumour diseases
10/16/2013EP2649998A1 Prolyl hydroxylase inhibitors
10/16/2013EP2649997A1 (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of antecedent hematologic disorders
10/16/2013EP2649995A2 Inhibition of post-radiation tumor growth
10/16/2013EP2649994A1 Combinations of aromatase inhibitors and antioxidants
10/16/2013EP2649183A1 Bispecific aptamers mediating tumour cell lysis
10/16/2013EP2649097A1 Anti ccr4 antibodies and uses thereof
10/16/2013EP2649095A2 Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
10/16/2013EP2649084A1 Novel derivatives of oxazaphosphorines that are pre-activated, use and method of preparation
10/16/2013EP2649078A1 4-aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
10/16/2013EP2649070A1 Triazolopyridine compounds
10/16/2013EP2649063A1 Triazole derivatives as wnt signaling pathway inhibitors
10/16/2013EP2648766A1 Psma-targeted dendrimers
10/16/2013EP2648762A2 Post-treatment breast cancer prognosis
1 ... 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 ... 2211